Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.49 |
| ▸ | FNTA | P49354 | 3/20 | 0.44 |
| ▸ | FNTB | P49356 | 3/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879678 | 0.79 | CDK5 (0.41) | CYP11B2MEN1KMT2A | |
| SCHEMBL3873541 | 0.77 | CYP11B2 (0.56) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL9046214 | 0.75 | CYP11B1 (0.60) | CYP11B2CYP11B1FNTAFNTB | |
| SCHEMBL30746942 | 0.74 | MAPK1 (0.46) | KMT2A | |
| SCHEMBL14151659 | 0.74 | CYP11B1 (0.32) | CYP11B2CYP11B1 | |
| SCHEMBL3819729 | 0.73 | CYP11B2 (0.78) | CYP11B2CYP11B1FNTAFNTB | |
| SCHEMBL13160969 | 0.72 | CYP11B1 (0.50) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL30718589 | 0.71 | CYSLTR1 (0.43) | CYP11B2CYP11B1MEN1KMT2A | |
| SCHEMBL6170674 | 0.71 | HIF1A (0.44) | MEN1KMT2A | |
| SCHEMBL9342265 | 0.70 | RXRA (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | FBP1, ALDOA, GYS2 | CYP11B2 120/4885CYP11B1 68/4885FNTA 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.